The USPTO published application US20260092284A1 covering mammalian cell lines engineered to produce adeno-associated viruses (AAVs) and methods for their use. The disclosure relates to nucleic acids encoding helper genes and AAV genes under inducible promoters, enabling controlled AAV production. CPC classifications indicate applications in gene therapy vector manufacturing (C12N 15/635, C07K 14/005).

This is a routine patent application publication rather than a regulatory action. Companies developing gene therapy products or AAV-based vectors may wish to review the claims to assess potential freedom-to-operate implications. No compliance deadlines or regulatory requirements are associated with this patent application publication.